Cardiovascular Research Foundation Ventures

Cardiovascular Research Foundation Ventures is the innovation fund of the CRF, a New York-based organization with deep standing in interventional cardiology research and clinical education. The fund’s mandate is narrow by design: breakthrough interventional cardiology devices and cardiovascular disease treatments, the same categories the parent organization has been working in for decades. Investment activity concentrates in medical devices and medtech, particularly hardware and procedure-enabling technology rather than digital or services-led companies. Limited public information is available on a named investment team or detailed portfolio in standard venture format, consistent with a corporate venture entity housed inside a research foundation rather than a standalone fund.

The fund deploys at Pre-Seed and Seed stages with check sizes under $250k, sizing that reflects an early catalytic role rather than a primary lead position. The check profile is most useful for very early companies that need first capital, validation, and access to interventional cardiology networks rather than full institutional rounds. Geographic focus is United States-anchored, with strong natural ties to the interventional cardiology community CRF has cultivated through its conferences, research, and clinical programs.

For founders, the strategic value of CRF Ventures often outweighs the dollar size. Cardiovascular device companies live or die based on physician adoption, trial design, and credibility within the interventional community, and a CRF-affiliated investor brings a kind of standing that ordinary seed capital cannot replicate. Founders should engage with the fund when a CRF relationship would change clinical access, key opinion leader engagement, or trial site recruitment. Teams outside interventional cardiology, including most software and services healthcare companies, are not the right fit for the mandate.